ACC 25: Cardiac Biomarker Analysis from The EARLY TAVR Trial in Patients With Asymptomatic Severe AS

1 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.

Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in patients with asymptomatic severe AS.

Findings showed that higher biomarker levels were associated with worse outcomes in the EARLY-TAVR trial, however, regardless of baseline biomarkers, there was a benefit to early TAVR compared to clinical surveillance. The benefit of early TAVR was consistent across subgroups.

Interview Questions:
1. Could you remind us of the main aim and study design of EARLY-TAVR?
2. What were the main research questions for this substudy in regard to biomarkers?
3. What were the key findings?
4. What are your take-home messages?
5. What are the next steps?

Recorded on-site at ACC in Chicago, 2025.

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Category
Cardiology
Be the first to comment

Up Next